Journal: Cell reports
Article Title: De novo recovery of Ghana virus, an African bat Henipavirus, reveals differential tropism and attenuated pathogenicity compared to Nipah virus
doi: 10.1016/j.celrep.2026.117074
Figure Lengend Snippet: (A–E) Dose-response curves are shown for various small-molecule inhibitors against rGhV M-GS* (purple) and rNiV (orange). CHO-B2 cells were infected at an MOI of 0.05 and treated with (A) EIDD-2749, (B) GHP-88309, (C) remdesivir, (D) EIDD-1931 (molnupiravir active form), or (E) favipiravir (T-705). (F and G) Additional dose-response curves were measured in primary human astrocytes for (F) EIDD-2749 and (G) GHP-88309 under the same MOI and assay conditions. (H) Summary of half-maximal inhibitory concentrations (IC 50 ) derived from the dose-response curves in (A–G). Each row indicates the respective compound, virus, calculated IC 50 , corresponding 95% confidence interval, and the cell type in which the assay was performed. IC 50 values were determined in GraphPad Prism by nonlinear regression of (inhibitor) vs. normalized response. All experiments were conducted in biological triplicate. Error bars depict standard deviation.
Article Snippet: Compounds employed in this study include EIDD-2749 (MedChemExpress, HY-146246), GHP-88309 (Sigma Aldrich, SML2997), EIDD-1931 (MedChemExpress, HY-125033), Remdesivir (MedChemExpress HY-104077), and Favipiravir (Cellagen Technology, C8705–5).
Techniques: Infection, Derivative Assay, Virus, Standard Deviation